Journal Information
Vol. 6. Issue 4.
Pages 214-216 (July - August 2010)
Share
Share
Download PDF
More article options
Vol. 6. Issue 4.
Pages 214-216 (July - August 2010)
Full text access
Resistant orbital pseudotumor treated with rituximab in a patient with systemic lupus erythematosus. A case presentation
Pseudotumor orbitario refractario tratado con rituximab en paciente con lupus eritematoso sistémico. A propósito de un caso
Visits
6177
Carmen María Escudero González
Corresponding author
carmenescu1@hotmail.com

Corresponding author.
, Sergio Rodríguez Montero, Rosalía Martínez Pérez, Carolina Pastor Mañosa, María Luisa Velloso Feijoo, José Luis Marenco de La Fuente
Servicio de Reumatología, Hospital Universitario Virgen de Valme, Sevilla, Spain
This item has received
Article information
Abstract

Ocular manifestations in Systemic Lupus Erythematosus (SLE) are relatively frequent, with a major prevalence of the Keratoconjunctivitis sicca. Nevertheless, the appearance of unilateral exophthalmos secondary to orbital pseudotumor in patients with SLE is extremely rare,1–7 and on occasion it can be refractory to conventional pharmacological treatment (glucocorticoids and immunosuppressants). We present the case of a patient with SLE and orbital pseudotumor refractory to treatment with Cyclophosphamide (CF) and an excellent clinical response, with disappearance of theo phthalmological condition after the beginning of therapy with Rituximab (1g×2), continuing after the infusion of two complete cycles without incidents.

Keywords:
Exophthalmos
Systemic lupus erythematosus
Orbital pseudotumor
Rituximab
Resumen

Las manifestaciones oculares en el lupus eritematoso sistémico (LES) son relativamente frecuentes, con mayor prevalencia de la queratoconjuntivitis seca. Sin embargo, la aparición de exoftalmos unilateral secundario a pseudotumor orbitario en pacientes con LES es extremadamente rara,1–7 y en ocasiones puede presentarse refractaria al tratamiento farmacológico convencional (glucocorticoides e inmunosupresores). A continuación presentamos el caso de una paciente con LES y pseudotumor orbitario refractario a tratamiento con ciclofosfamida y excelente respuesta clínica con desaparición de la clínica oftalmológica tras el inicio de la terapia con rituximab (1g × 2), eficacia mantenida tras la infusión de dos ciclos completos sin incidencias.

Palabras clave:
Exoftalmos
Lupus eritematoso sistémico
Pseudotumor orbitario
Rituximab
Full text is only aviable in PDF
References
[1.]
S. Serop, R.N. Vianna, M. Claeys, J.J. De Laey.
Orbital myositis secondary to systemic lupus erythematosus.
Acta Ophthalmol (Copenh), 72 (1994), pp. 520-523
[2.]
A.D. Bankhurst, T.J. Carlow, R.W. Reidy.
Exophthalmos in systemic lupus erythematosus.
Ann Ophthalmol, 6 (1984), pp. 669-671
[3.]
S. Siebert, U. Srinivasan.
Proptosis can be the presenting feature of systemic lupus erythematosus.
Ann Rheum Dis, 63 (2004), pp. 908-909
[4.]
D.R. Jordan, H. McDonald, B. Olberg, D. McKim, R. McKendy.
Orbital panniculitis as the initial manifestation of systemic lupus erythematosus.
Ophthal Plast Reconstr Surg, 9 (1993), pp. 71-75
[5.]
B.S. Grimson, K.B. Simons.
Orbital inflammation, myositis, and systemic lupus erythematosus.
Arch Ophthalmol, 101 (1983), pp. 736-738
[6.]
R.E. Feinfield, R.J. Hesse, S.A. Rosenberg.
Orbital inflammatory disease associated with systemic lupus erythematosus.
South Med J, 84 (1991), pp. 98-99
[7.]
L.S. Wildinson, R.S. Panush.
Exophthalmos associated with systemic lupus erythematosus.
Arthritis Rheum, 18 (1975), pp. 188-189
[8.]
N.G. Snebold.
Orbytal pseudotumor syndromes.
Curr Opin Ophthalmol, 8 (1997), pp. 41-44
[9.]
L.K. Gordon.
Diagnostic dilemmas in orbital inflammatory disease.
Ocul Immunol Inflamm, 11 (2003), pp. 3-15
[10.]
R.E. Gray, E.A. Jenkins, M.A. Hall, J.J. Kanski, B.M. Ansell.
Recurrent acute proptosis in atypical systemic lupus erythematosus.
Clin Rheumatol, 8 (1989), pp. 528-532
[11.]
T. Miquel, S. Abad, I. Badelon, C. Vignal, U. Warzocha, C. Larroche, et al.
Successful treatment of idiopathic orbital inflammation with infliximab: an alternative to conventional steroid-sparing agents.
Ophthal Plast Reconstr Surg, 24 (2008), pp. 415-417
[12.]
M.K. Kapadia, P.A. Rubin.
The emerging use of TNF-alpha inhibitors in orbital inflammatory disease.
Int Ophthalmol Clin, 46 (2006), pp. 165-181
[13.]
M.D. Schafranski.
Idiopathic orbital inflammatory disease successfully treated with Rituximab.
Clin Rheumatol, 28 (2009), pp. 225-226
[14.]
M. Salvi, G. Vannucchi, I. Campi, N. Currò, D. Dazzi, S. Simonetta, et al.
Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: An open study.
Eur J Endocrinol, 156 (2007), pp. 33-40
[15.]
M. Salvi, G. Vannucchi, I. Campi, N. Currò, P. Beck-Peccoz.
New immunomodulators in the treatment of Graves’ ophthalmopathy.
Ann Endocrinol (Paris), 69 (2008), pp. 153-156
[16.]
P.P. Sfikakis, J.N. Boletis, G.C. Tsokos.
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
Curr Opin Rheumatol, 17 (2005), pp. 550-557
[17.]
C. Melander, M. Sallée, P. Trolliet, S. Candon, X. Belenfant, E. Daugas, et al.
Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.
Clin J Am Soc Nephrol, 4 (2009), pp. 579-587
[18.]
J. Yan, Z. Wu, Y. Li.
The differentiation of idiopathic inflammatory pseudotumor from lymphoid tumors of orbit: analysis of 319 cases.
Copyright © 2010. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
Download PDF
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?